Fluorodeoxyglucose positron emission tomography/computed tomography findings after percutaneous cryoablation of early breast cancer

Abstract

Background: To document 18 F-Fluorodeoxyglucose positron emission tomography/computed tomography (PET/ CT) findings after percutaneous cryoablation for early breast cancer. Methods: Data of 193 consecutive patients who had undergone cryoablation for invasive ductal carcinoma or ductal carcinoma in situ ≤ 15 mm without a history of ipsilateral breast cancer, synchronous ipsilateral lesion, and with estrogen receptor positive/human epidermal growth factor 2 negative were enrolled. The imaging characteristics of the treated areas were evaluated and classified on CT images as one of two types: fatty mass or non-fatty mass type. The maximum standardized uptake value (SUVmax) of the initial post-cryoablation PET/CT, the CT type of the treated area and selected clinical factors (age, menopausal status, lesion area, breast density, timing of PET/CT) were retrospectively evaluated. Results: The median interval between cryoablation and the initial post-cryoablation PET/CT was 12 months. The median SUVmax of the treated area was 1.36. The CT findings of the treated area were classified as fatty mass type (n = 137, 71.0%) or non-fatty mass type (n = 56, 29.0%). The treated areas of patients with lower breast density, of older age, post-menopausal status, and lower radiation dose were significantly more likely to be of fatty mass type (P < 0.001). Non-fatty mass type averaged a significantly higher SUVmax than did fatty mass type.

Percutaneous Ultrasound-Guided Cryoablation for Early-Stage Primary Breast Cancer- A follow-up study in Japan

“…The results of the trial, reported by Simmons et al [15] showed a success rate of 75.9% (66/87) for cryoablation. The current study, performed with the same cryoablation system as in Fine et al, showed higher local control rates, although with a smaller sample size Currently, there are only a few published studies of imaging ndings following breast cancer cryoablation [21,22] and to the best of our knowledge, none with long-term ndings. In the present report, MRI following cryoablation revealed a consistent cryolesion volume reduction for all patients up to 5 years post-procedure.…”

“…Cryotherapy has shown similar results to RFA in terms of local control rate and tolerability [31][32][33][34][35][36][37][38][39], and it is expected to be incorporated into clinical practice in the same way as RFA. In the past few years, multiple centers, both domestic and international, have reported excellent local control rates with percutaneous cryoablation for early-stage, low-risk breast cancer tumors smaller than 15 mm from [20][21][22]40]. Percutaneous cryoablation has the potential to be an alternative to lumpectomy with promising oncologic results and favorable cosmetic outcomes performed under local anesthesia on an outpatient basis, ensuring a short recovery period for patients.…”

Breast Cancer Cryoablation in the Multidisciplinary Setting: Practical Guidelines for Patients and Physicians

“…Among patients undergoing FDG-PET/CT within 12 months of cryoablation, Adachi et al report a median maximum standard value unit (SUVmax) of 1.36, which is generally considered benign. In general, the SUVmax was typically significantly higher in younger women, pre-menopausal women, and in those with higher breast density [ 51 ].…”

“…Life 2022, 12, x FOR PEER REVIEW 29 of 33 typically significantly higher in younger women, pre-menopausal women, and in those with higher breast density [51]. Despite its inability to completely exclude recurrence or residual disease, serial FDG-PET/CT performed for other reasons might demonstrate a loss or decrease in activity at the cryoablation site, which is considered a benign feature.…”

Cryogenic Media in Biomedical Applications: Current Advances, Challenges, and Future Perspectives

“…Patients with a pure IDC, ductal carcinoma in situ (DCIS) with EIC, or invasive lobular carcinoma (ILC) should be excluded. Since, according to the vast majority of supportive studies, the size of tumour has been found to be an essential predictor of residual cancer, US, MRI and mammography assessment together with multiple core biopsies of the tissues surrounding the tumour are required for optimal patient selection, as well in vivo 38: 1-39 (2024) as to exclude extensive intraductal components associated with the lack of cryosurgery radicality and thus with diminishing modality efficiency (122,124,(126)(127)(128)(129)(130)(131).…”